Cargando…
Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections
Drugs called CFTR modulators improve the physiologic defect underlying cystic fibrosis (CF) and alleviate many disease manifestations. However, studies to date indicate that chronic lung infections that are responsible for most disease-related mortality generally persist. Here, we investigated wheth...
Autores principales: | Durfey, Samantha L., Pipavath, Sudhakar, Li, Anna, Vo, Anh T., Ratjen, Anina, Carter, Suzanne, Morgan, Sarah J., Radey, Matthew C., Grogan, Brenda, Salipante, Stephen J., Welsh, Michael J., Stoltz, David A., Goss, Christopher H., McKone, Edward F., Singh, Pradeep K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669489/ https://www.ncbi.nlm.nih.gov/pubmed/34903059 http://dx.doi.org/10.1128/mbio.03148-21 |
Ejemplares similares
-
Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations
por: Hardisty, Gareth R., et al.
Publicado: (2021) -
Ivacaftor decreases monocyte sensitivity to interferon-γ in people with cystic fibrosis
por: Hisert, Katherine B., et al.
Publicado: (2020) -
A population-level strain genotyping method to study pathogen strain dynamics in human infections
por: Morgan, Sarah J., et al.
Publicado: (2021) -
Ivacaftor, not ivacaftor/lumacaftor, associated with lower pulmonary inflammation in preschool cystic fibrosis
por: Shanthikumar, Shivanthan, et al.
Publicado: (2022) -
Tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2019)